Valuation: Vericel Corporation

Market Cap 2.4B 2.1B 1.93B 1.8B 3.4B 228B 3.46B 23.18B 8.98B 112B 9.01B 8.81B 386B P/E 2026 *
99.4x
P/E 2027 * 53.6x
Enterprise Value 2.4B 2.1B 1.93B 1.8B 3.4B 228B 3.46B 23.18B 8.98B 112B 9.01B 8.81B 386B EV / Sales 2026 *
7.22x
EV / Sales 2027 * 6.17x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day+4.05%
1 week+9.51%
Current month+5.60%
1 month+36.37%
3 months+37.61%
6 months+31.93%
Current year+30.46%
1 week 43.53
Extreme 43.53
47.06
1 month 35.38
Extreme 35.38
47.06
Current year 28.95
Extreme 28.95
47.06
1 year 28.95
Extreme 28.95
47.06
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 2013-02-28
Director of Finance/CFO 51 2021-01-24
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 71 2005-09-27
Chairman 75 2012-10-04
Director/Board Member 57 2013-08-22
Date Insider Type Main position Quantity % Market Cap.
06-25Sell

Controller/Auditor

-7,732 0.0151%
06-25Fiscal year

General Counsel

45,000 0.0881%
06-25Fiscal year

Chief Technology Officer

30,000 0.0587%
Change 5-day change 1-year change 3-year change Capi.($)
+4.05%+9.51%+13.31%+25.05% 2.4B
+4.73%+5.50%+19.45%-8.94% 66.56B
-1.93%+0.54%+58.86%+226.84% 57.64B
+1.07%+42.10%+42.10%+42.10% 42.24B
+3.45%+3.54%-49.20%-56.09% 39.09B
-4.05%+7.01%+62.26%-24.13% 31.91B
-1.99%+33.49%+163.41%-34.35% 31.65B
-0.28%+8.68%+71.42%+87.73% 23.35B
+2.87%+15.37%+10.72%+196.62% 18.92B
-0.13%+2.79%+67.55%+130.16% 17.17B
Average +3.00%+5.02%+45.99%+58.50% 33.09B
Weighted average by Cap. +2.81%+4.28%+44.61%+55.21%

Financials

2026 *2027 *
Net sales 332M 290M 267M 249M 471M 31.63B 479M 3.21B 1.24B 15.51B 1.25B 1.22B 53.45B 389M 340M 312M 291M 551M 37B 561M 3.76B 1.46B 18.15B 1.46B 1.43B 62.54B
Net income 24.64M 21.53M 19.77M 18.44M 34.95M 2.35B 35.54M 238M 92.24M 1.15B 92.51M 90.5M 3.96B 46.36M 40.51M 37.2M 34.69M 65.76M 4.41B 66.87M 448M 174M 2.16B 174M 170M 7.46B
Net Debt - -
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
26-07-02 US$46.98 +4.05% 640,729
26-07-01 US$45.15 +1.48% 613,541
26-06-30 US$44.49 -1.29% 743,284
26-06-29 US$45.07 -2.51% 772,104
26-06-26 US$46.23 +7.76% 2,336,227
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
46.98USD
Average target price
55.43USD
Spread / Average Target
+17.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VCEL Stock